Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
|
|
- Eustace Snow
- 6 years ago
- Views:
Transcription
1 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
2 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical (including performance status and weight loss evaluation) 3. CBC, platelets, chemistry profile 4. CT chest, upper abdomen including adrenals 5. PET scan when clinically indicated 6. Brain MRI for stage II and above 7. Bronchoscopy 8. EBUS when clinically indicated 9. Mediastinoscopy when clinically indicated 10. Smoking cessation counseling Pathologic Review: For classification of lung cancer type, extent of invasion, involvement status or surgical margins. Determination of abnormalities which predict for sensitivity vs. resistance to EGFR-TKI s (EGFR mutations exon 19 deletion, exon 21 mutation and exon 18, KRAS mutation) Tumor classification system used is defined by WHO Immunohistochemistry: TTF-1: distinguishes primary from metastatic adenocarcinoma; majority of primary lung cancer is positive for TTF-1; metastatic adenocarcinoma is almost always negative for TTF-1 Pulmonary adenocarcinoma usually is CK7+/CK20-; metastatic adenocarcinoma of colorectal origin usually is CK7-/CK20+. CDX-2 is sensitive and specific for primary GI malignancies. Chromogranin and Synaptophysin are usually positive in neuroendocrine tumors including all carcinoid, but are negative in 25% of small cell lung cancer cases
3 Staging: IASLC Lung Cancer Staging Project, J Thorac Oncol 2007;2: Tumor: TX T0 Tis T1 T1a T1b T2 T2a T2b T3 T4 Lymph Nodes: NX N0 N1 N2 N3 Primary tumor cannot be assessed No evidence of primary tumor Carcinoma in situ Tumor 3 cm surrounded by lung or visceral pleura, w/o bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e. not main bronchus) Tumor 2 cm Tumor >2 cm but 3 cm Tumor >3 cm but 7 cm or with any of the following: -Involves the main bronchus, 2 cm distal to carina -Invades visceral pleura -Associated atelectasis or obstructive pneumonitis which extends to hilar region but does not involve the entire lung Tumor >3 cm but 5 cm Tumor >5 cm but 7 cm Tumor >7 cm or one that directly invades any of the following: -chest wall (including superior sulcus tumors), diaphragm, pherecnic nerve, mediastinal pleura, paretal pericardium -Tumor in the main bronchus <2 cm distal to carina, w/o involvement of carina -Associated atelectasis of obstructive pneumonitis of the entire lung -Separate tumor nodule in the same lobe Tumor of any size that invades any of the following: -mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina -Separate tumor nodule in a different ipsilateral lung Regional lymph nodes cannot be assessed No regional lymph node metastasis Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension Metastasis in ipsilateral mediastinal and/or subcarinal lymph node Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node Distant Metastasis: MX Distant metastasis cannot be assessed M0 No distant metastasis M1a Separate tumor nodule in contralateral lung; malignant pleural nodules or effusion M1b Distant metastasis
4 Stage IA T1a,N0,M0 T1b,N0,M0 Stage IB Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IV T2a,N0,M0 T1a,N1,M0 T1b,N1,M0 T2a,N1,M0 T2b,N0,M0 T2b,N1,M0 T3,N0,M0 T4(same lobe),n0,m0 T3,N1,M0 T3,N2,M0 T4(same lobe),n1,m0 T4(same lobe),n2,m0 T4(extension),N0,M0 T4(extension),N1,M0 T4(ipsilateral lung M1),N0,M0 T4(ipsilateral lung M1),N1,M0 T4(extension),N2,M0 T4(ipsilateral lung M1),N2,M0 Any T,N3,M0 Any T, Any N,M1a Any T, Any N,M1b
5 1. Resectable/Early Stage (TNM stage I, II, some IIIA) A. Surgical candidate: Surgery Lobectomy is preferred over segmentectomy or wedge resection. Lung sparing anatomic resection or sleeve lobectomy preferred over pneumonectomy B. Not a surgical candidate : SBRT for peripheral lesions C. Adjuvant Chemotherapy (T2,N0-high risk*; T3,N0; T1-T3,N1-N2) *High risk: poorly differentiated tumors, vascular invasion, wedge resection, minimal margins, tumors >4cm, visceral pleural involvement, unknown nodal status) D. Positive margins: Re-resection or chemo-radiotherapy
6 2. Superior sulcus tumor (T3-T4 N0 or N1): Neo-adjuvant chemo-radiotherapy followed by surgery preferred treatment or Definitive chemo-radiotherapy 3. Single N2 lymph node <3cm can be approached with Neo-adjuvant chemotherapy or chemo-radiotherapy followed by evaluation for surgery
7 2. Locally Advanced Disease (Unresectable IIIA, IIIB) A. Concurrent Chemo-radiotherapy : a) Clinical trial b) Concurrent chemo-radiotherapy c) Consolidation chemotherapy following concurrent chemo-radiotherapy
8 4. Advanced Disease (M1) a) Clinical trial b) Palliative chemotherapy c) Targeted therapy d) Maintenance therapy e) Second/Third line therapy
9 Chemotherapy regimens: A) Adjuvant chemotherapy Published regimens: a. Cisplatin 50mg/m2, days 1 and 8 Vinorelbine 25mg/m2, days 1,8,15,22 (Q28 days X 4 cycles) b. Cisplatin 100mg/m2, on day 1 Vinorelbine 30mg/m2, days 1,8,15,22 (Q28 days X 4 cycles) c. Cisplatin 75-80mg/m2, on day1 Vinorelbine 25-30mg/m2, days 1 and 8 (Q21 days X 4 cycles) d. Cisplatin 100mg/m2, on day 1 Etoposide 100mg/m2, days 1-3 (Q28 days X 4 cycles) e. Cisplatin 80mg/m2 on day 1,22,43,64 Vinblastine 4mg/m2, days 1,8,15,22 then Q2 wk after day 43 (Q21 days X 4 cycles) 2. Regimen for patients with comorbidities or not able to tolerate cisplatin: Carboplatin AUC 6, on day 1 Paclitaxel 200mg/m2, on day 1 (Q21 days)
10 B) Concurrent chemo-radiotherapy for locally advanced disease*: a) Clinical trial Cisplatin 50mg/m2, on day 1,8,29 and 36 Etoposide 50mg/m2 days 1-5, Concurrent thoracic RT (total dose 61 Gy) Followed by histology based consolidation Non-squamous histology: Pemetrexed 500mg/m2 IV q 21 days for 4 cycles Squamous histology: Gemcitabine 1000mg/m2 days 1,8 q 21 days for 4 cycles b) Cisplatin 50mg/m2, on day 1,8,29 and 36 Etoposide 50mg/m2 days 1-5, Concurrent thoracic RT (total dose 61 Gy) c) Cisplatin 100mg/m2, day 1 and 29 Vinblastine 5mg/m2, weekly X 5 Concurrent thoracic RT(total dose 60 Gy) d) Paclitaxel 45-50mg/m2 weekly over 1 hour Carboplatin AUC 2 over 30mg weekly Concurrent thoracic RT 63 Gy/7 weeks, 34 fractions e) Consolidation Chemotherapy for T4, N2-3 Following Cisplatin/Etoposide as above: a. Cisplatin 50mg/m2 and etoposide 50mg/m2 X 2 additional cycles(category 2B) Following Carboplatin/Paclitaxel as above: b. Paclitaxel 200mg/m2 and Carboplatin AUC 6 X 2 additional cycles(category 2B) *Randomised data supports use of cisplatin vs. carboplatin-based regimens
11 C) Advanced M1 disease a) S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizu-mab with or without Concurrent Cetuximab in Patients Advanced Non-Small Cell Lung Cancer (NSCLCClinical trial SWOG b) C A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung CancerCALGB c) Non-squamous histology: Do EGFR testing i) EGFR mutation positive Erlotinib first line preferred ii) EGFR mutation negative/unkown: Chemotherapy preferred d) Non-squamous histology chemotherapy regimens i) Chemotherapy alone ii) Chemotherapy +bevacizumab if criteria met e) Squamous histology i) Chemotherapy alone Pemetrexed and bevacizumab not indicated in squamous histology Cisplatin or carboplatin are each effective in combination with any of the following: paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, pemetrexed (non-squamous) Preferred regimen: Carboplatin AUC 6 and Paclitaxel 175mg/m2 q 21 days +/- bevacizumab Carboplatin AUC 6 and Pemetrexed 500mg/m2 q 21 days +/- bevacizumab
12 f) Maintenance regimen: Non-squamous histology: i) Pemetrexed 500mg/m2 IV q 21 days ii) Erlotinib 150mg PO daily iii) Bevacizumab 15mg/kg IV q 21 days Squamous histology: i) Erlotinib 150 mg PO daily g) Second line chemotherapy: 1. Docetaxel single-agent is superior to best supportive care 2. Pemtrexed single-agent superior to docetaxel with less toxicity in patients with adenocarcinoma and large cell carcinoma 3. Erlotinib single-agent is superior to best supportive care with significantly improved survival and delayed time to symptom deterioration h) Third-Line: Erlotinib is superior to best supportive care with significantly improved survival
North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationLung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationCase Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationSeventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams
CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationCollecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationNon small cell Lung Cancer
Non small cell Lung Cancer The 13th refresher course for residents in radiation oncology Jiraporn Setakornnukul, M.D. Radiation oncology division, Radiology department Siriraj Hospital, Mahidol University
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationAJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
More information6 th Reprint Handbook Pages AJCC 7 th Edition
6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationLung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence
LUNG CANCER 2010 Mark B. Stoopler, M.D. Division of Medical Oncology Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationLUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL
LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL ( ) Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE
More information3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5
LUNG CANCER 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Very common Very lethal Lung Cancer Median age of diagnosis approximately 70 years, but affects all ages(even pediatric!) Advances in
More informationLung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%
Multidisciplinary approach 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Neurology Neurosurgery Orthopedic surgery General surgery Vascular surgery Gastroenterology Cardiology Lung Cancer Very
More informationImaging of Lung Cancer: A Review of the 8 th TNM Staging System
Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationLung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:
1 NAACCR 2015-2016 Webinar Series Collecting Cancer Data: Lung NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org Q&A Please submit all
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)
No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationLung cancer LUNG CANCER. Box 1 Clinical signs
22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting
More informationLungStage. Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies
LungStage Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies Medical Team: Bram Stieltjes, MD PhD; Alex Sauter, MD; Gregor Sommer, MD;
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationLung and Aerodigestive malignancies
Lung and Aerodigestive malignancies Nabil F Saba MD, FACP Professor, Director of the Head and Neck Oncology Program, Winship Cancer Institute Emory University COI I am a consultant for GSK, Merck, BMS,
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More information11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationManagement of Lung Cancer in Older Adults
Management of Lung Cancer in Older Adults Arti Hurria, MD; Mark G. Kris, MD ABSTRACT Lung cancer is the leading cause of cancer death in the United States. At the time of diagnosis, most patients are older
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationStaging of lung cancer provides a common language
The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationTable 1 Major Classifications of Lung Cancer. Non Small Cell Lung Cancer Adenocarcinoma
VIII LUNG CANCER Jeffrey Crawford, m.d. Definition and Classifications Bronchogenic carcinoma of the lung lung cancer comprises a group of malignant neoplasms that arise from bronchial epithelium. The
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationLung Cancer: Determining Resectability
Lung Cancer: Determining Resectability Leslie E. Quint lequint@umich.edu No disclosures Lung Cancer: Determining Resectability AIM: Review imaging features that suggest resectability / unresectability
More informationLung Cancer. Management of (2006) Philippine Society of Medical Oncology. Governing Council Offi cers. Council Members.
Management of Lung Cancer (2006) Philippine Society of Medical Oncology Unit 1418, 14/F, orth Tower, Cathedral Heights Bldg. St. Luke s Medical Center. E. Rodriguez Sr. Avenue Quezon City 1099, Philippines
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationNeues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom. J. Pfannschmidt
Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom J. Pfannschmidt Immunhistochemie durchgängig zur Klassifizierung Integration der molekularen Analyse Neuklassifizierung
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationGROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationTumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma
Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationMediastinal Mysteries: What can be solved with EBUS?
Mediastinal Mysteries: What can be solved with EBUS? W. Graham Carlos MD Pulmonary & Critical Care Fellow Indiana University School of Medicine Disclosures None Objectives Introduce you to the technique
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationNCCN Guidelines for Patients
Non-Small Cell Lung Cancer NCCN Guidelines for Patients Version 2010 In honor and memory of Dana Reeve Also available at NCCN.com Non-Small Cell Lung Cancer Table of Contents Map of the NCCN Member Institutions...
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More information